Neurizon Hits 50% Dosing in Expanded ALS Trial 12 Months From Data Readout
Neurizon passes 50% dosing milestone in expanded HEALEY ALS Platform Trial
Neurizon Therapeutics has announced that 129 of 240 participants have now been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease. As at 9 June 2026, 167 participants had been assigned to Regimen I, with 78 clinical trial sites now activated across the United States.
The milestone was achieved shortly after Regimen I was expanded from 160 to 240 participants. Recruitment and dosing momentum is tracking ahead of expectations, reflecting strong engagement from investigators, clinical sites and the ALS community.
Recruitment momentum continues to track ahead of expectations and Neurizon remains well positioned for its stated milestones.
When big ASX news breaks, our subscribers know first
What is a platform trial and why does it matter?
A platform trial tests multiple therapies using shared infrastructure, a common control group and a single protocol. This design accelerates development timelines and reduces costs compared to standalone trials.
The HEALEY ALS Platform Trial is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 trial. Entry is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The platform is conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in partnership with the Network of Excellence for ALS (NEALS).
NUZ-001’s inclusion in the platform signals it met a high scientific bar for selection, providing independent validation of the therapy’s potential.
Trial expansion supports larger dataset
Regimen I was expanded from 160 to 240 participants following stronger than anticipated recruitment rates. The expansion also reflects the absence of a concurrent regimen during the recruitment period.
The trial expansion to 240 participants was announced in May 2026, driven by enrolment rates significantly exceeding original expectations, with management confirming no change to funding requirements as philanthropic contributions and R&D tax incentives offset the incremental costs.
The expanded study is intended to support a larger and more informative dataset. The original statistical assumptions underpinning the primary efficacy analysis are maintained.
| Trial Parameter | Figure |
|---|---|
| Original Regimen I size | 160 participants |
| Expanded Regimen I size | 240 participants |
| Participants dosed (as at 9 June 2026) | 129 |
| Participants assigned (as at 9 June 2026) | 167 |
| Clinical sites activated (US) | 78 |
A larger dataset improves the robustness of efficacy findings, potentially strengthening the regulatory, partnering and commercial positioning of NUZ-001 if results are positive.
Timeline to topline results
Neurizon expects to reach the following milestones:
- Last participant dosing: Q2 CY2027
- Topline results: Early Q3 CY2027
Timelines remain subject to ongoing recruitment rates and operational factors. The 50% dosing milestone supports confidence in these timelines, providing clear visibility on the path to a potential catalyst in H2 CY2027.
Executive commentary
Interim Executive Chairman Sergio Duchini
“Surpassing the 50% dosing milestone in Regimen I represents another important achievement for the NUZ-001 program and provides further evidence of the strong execution capabilities of the HEALEY ALS Platform Trial network. Importantly, this milestone has been achieved shortly after the expansion of the study from 160 to 240 participants, highlighting the continued enthusiasm from investigators, clinical sites and the ALS community, as well as the efficiency of the platform in progressing patients through recruitment, screening, randomisation and treatment.”
Duchini emphasised confidence in the operational timelines and the potential for a robust dataset to support future regulatory, partnering and commercial opportunities.
The next major ASX story will hit our subscribers first
Investment thesis
NUZ-001 is progressing through a well-designed Phase 2/3 platform trial with operational momentum exceeding expectations. The expanded trial supports a more robust dataset without delaying timelines, while recruitment rates ahead of forecast reduce execution risk.
The potential near-term catalyst of topline results in early Q3 CY2027 provides investors with clear visibility on a data readout approximately 12 months away. Positive data could support regulatory, partnering and commercial opportunities, materially re-rating the company.
Neurizon is executing ahead of schedule on a clearly defined clinical pathway, with the 50% dosing milestone representing tangible evidence of the platform’s operational strength and the continued engagement of the ALS community.
For investors exploring the financial structure behind the program, our full explainer on how Neurizon funded the HEALEY trial details the three-part $44.2 million funding package, including the Obsidian convertible note facility and entitlement offer, that positioned the company to reach this operational stage without additional capital requirements.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment clinical trial updates and regulatory milestones hit the market.